Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Dolastatin-10. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin-10 SCHEMBL18793204 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13135112 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL12016480 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL5286 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL16730776 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13378458 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL23387006 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL6423272 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126283 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL14583139 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903929-B2 | Method for inhibiting dengue virus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11878004-B2 | Method for inhibiting Zika virus infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2024-01-23 | — | — | US | disclosed |
| US-11850236-B2 | Method for inhibiting Zika virus infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-12-26 | — | — | US | disclosed |
| US-11779570-B2 | Method for inhibiting dengue virus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220323420-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20200289471-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-09-17 | — | — | US | disclosed |
| US-20200197369-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903929-B2 | Method for inhibiting dengue virus infection | ZC3HAV1, MAVS, IRF3 | SSTR2 4842/4885CYP3A4 2021/4885FOLH1 4169/4885 |
| US-20220323420-A1 | METHOD FOR INHIBITING ZIKA VIRUS INFECTION | ZC3HAV1, MAVS, IRF3 | SSTR2 4826/4885CYP3A4 2378/4885FOLH1 4051/4885 |
| US-20200289471-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | MAVS, ZC3HAV1, EIF2AK2 | SSTR2 4832/4885CYP3A4 3107/4885FOLH1 4193/4885 |
| US-11878004-B2 | Method for inhibiting Zika virus infection | ZC3HAV1, MAVS, IRF3 | SSTR2 4826/4885CYP3A4 2378/4885FOLH1 4051/4885 |
| US-11850236-B2 | Method for inhibiting Zika virus infection | ZC3HAV1, MAVS, IRF3 | SSTR2 4826/4885CYP3A4 2378/4885FOLH1 4051/4885 |
| US-11779570-B2 | Method for inhibiting dengue virus infection | ZC3HAV1, MAVS, IRF3 | SSTR2 4842/4885CYP3A4 2021/4885FOLH1 4169/4885 |
| US-20200197369-A1 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | MAVS, ZC3HAV1, EIF2AK2 | SSTR2 4832/4885CYP3A4 3107/4885FOLH1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.